We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+13.81%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$2.23B
AUM Growth
-$82.9M
Cap. Flow
-$145M
Cap. Flow %
-6.5%
Top 10 Hldgs %
65.91%
Holding
64
New
5
Increased
3
Reduced
16
Closed
4

Top Buys

Rank Stock Value
1
WHWK
Whitehawk Therapeutics
WHWK
+$43.5M
2
SERA icon
Sera Prognostics
SERA
+$19.3M
3
VRDN icon
Viridian Therapeutics
VRDN
+$19.1M
4
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$14M
5
HRMY icon
Harmony Biosciences
HRMY
+$11.3M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$105M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$25.8M
3
CLDX icon
Celldex Therapeutics
CLDX
+$22.7M
4
LEGN icon
Legend Biotech
LEGN
+$19.5M
5
NVAX icon
Novavax
NVAX
+$18.7M

Sector Composition

Rank Sector Weight
1 Healthcare 85.61%
2 Financials 7.21%
3 Materials 7.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASLN
51
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$5.06M 0.23%
71,023
– –
LRMR icon
52
Larimar Therapeutics
LRMR
$433M
$4.61M 0.21%
399,830
-399,832
-50% -$4.8M
ELEV
53
DELISTED
Elevation Oncology
ELEV
$3.87M 0.17%
496,843
– –
EIGR
54
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$3.14M 0.14%
15,653
-44,056
-74% -$10.5M
ORTX
55
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$3.05M 0.14%
132,574
– –
TXG icon
56
10x Genomics
TXG
$5.79B
$2.15M 0.1%
14,798
– –
DTIL icon
57
Precision BioSciences
DTIL
$192M
$1.62M 0.07%
4,675
– –
ZGNX
58
DELISTED
Zogenix, Inc.
ZGNX
$1.59M 0.07%
105,000
– –
TCDA
59
DELISTED
Tricida, Inc. Common Stock
TCDA
$779K 0.04%
167,863
-6,900
-4% -$28.6K
MTCR
60
DELISTED
Metacrine, Inc. Common Stock
MTCR
$502K 0.02%
146,426
– –
CYTK icon
61
Cytokinetics
CYTK
$10.9B
– –
-700,000
Closed -$13.9M
IMVT icon
62
Immunovant
IMVT
$8.13B
– –
-532,847
Closed -$5.63M
NVAX icon
63
Novavax
NVAX
$1.25B
– –
-88,046
Closed -$18.7M
CALT
64
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
– –
-62,306
Closed -$1.83M
1 2
3

Similar funds

FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return
CS
Central Securities New York $1.21B AUM 19.91% 1-Year Est. Return
KOC
Koss-Olinger Consulting Gainesville, Florida $1.19B AUM 15.91% 1-Year Est. Return

Vivo Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Vivo Capital held 64 positions worth $2.23B, down 3.6% from $2.31B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Vivo Capital withdrew a net $145M in Q3 2021, closing 4 positions and reducing 16 holdings. Its most notable exit was Novavax, an estimated $18.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier, followed by Financials and Materials.

Against the trend, Vivo Capital opened a new position in Whitehawk Therapeutics worth $41.9M.

  • Vivo Capital's largest Q3 2021 buy was Whitehawk Therapeutics: 1,427,213 shares worth $41.9M.
  • Vivo Capital added most to Harmony Biosciences in Q3 2021, an estimated $11.3M increase.
  • Vivo Capital's biggest Q3 2021 reduction was Ascendis Pharma A/S, cutting an estimated $105M.
  • Vivo Capital fully exited Novavax in Q3 2021, selling an estimated $18.7M.
  • Vivo Capital's ten largest holdings make up 66% of its $2.23B portfolio in Q3 2021.
  • Vivo Capital opened 5 new positions and closed 4 in Q3 2021.
  • Vivo Capital's portfolio value fell 3.6% quarter-over-quarter to $2.23B.

Based on Vivo Capital's 13F filing for Q3 2021, filed 15 Nov 2021.